scholarly journals Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials

2018 ◽  
Vol 93 (7) ◽  
pp. 921-930 ◽  
Author(s):  
James Bussel ◽  
Donald M. Arnold ◽  
Elliot Grossbard ◽  
Jiří Mayer ◽  
Jacek Treliński ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Controlled Trials ◽  
Phase 3 ◽  
Two Phase ◽  
Chronic Immune Thrombocytopenia

scholarly journals Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis

2021 ◽  
Vol 5 (1) ◽  
pp. s9
Author(s):  
Jonathan Silverberg ◽  
Sebastien Barbarot ◽  
Melinda Gooderham ◽  
Jan Simon ◽  
Eric Simpson ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Controlled Trials ◽  
Phase 3 ◽  
Two Phase ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Interleukin 13

Abstract not available.

scholarly journals Fostamatinib for the treatment of chronic immune thrombocytopenia

Blood ◽  
2019 ◽  
Vol 133 (19) ◽  
pp. 2027-2030 ◽  
Author(s):  
Nathan T. Connell ◽  
Nancy Berliner
Keyword(s):  
Immune Thrombocytopenia ◽  
Kinase Inhibitor ◽  
Phase 3 ◽  
Clinical Safety ◽  
Randomized Controlled ◽  
Multicenter Phase ◽  
Adequate Response ◽  
Line Of Therapy ◽  
Chronic Immune Thrombocytopenia

Abstract Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 prior line of therapy. This article reviews fostmatinib’s mechanism of action and its clinical safety and efficacy in 2 industry-sponsored multicenter phase 3 randomized controlled trials in North America, Australia, and Europe (FIT1 and FIT2). Cost comparisons are discussed as well as the role of fostamatinib in relation to other options for chronic ITP.

Sign in / Sign up

Export Citation Format

Share Document